FDA Approved: DEXYCU — Supplemental Application (EyePoint Pharmaceuticals US, Inc)

View source ↗

Summary

FDA approved a supplemental application for DEXYCU (dexamethasone intraocular suspension) to expand its label for postoperative ocular inflammation management.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Postoperative Ocular Inflammation

Drugs mentioned

• Dexycu (dexamethasone intraocular suspension)

Snippet

SUPPL AP for DEXYCU (DEXAMETHASONE)